Hikma Pharmaceuticals Overview
- Founded
- 1978
- Status
- Public
- Employees
- 8,600
- Stock Symbol
- HIK
- Investments
- 19
- Share Price
- $34.75
- (As of Friday Closing)
Hikma Pharmaceuticals General Information
Description
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
LON
Primary Office
- 1 New Burlington Place
- London W1S 2HR
- England, United Kingdom
+44 020 0000 0000
Hikma Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $34.75 | $35.39 | $18.75 - $36.80 | $8.16B | 230M | 568K | $2.12 |
Hikma Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 6,529,219 | 6,688,814 | 5,750,556 | 4,294,666 |
| Revenue | 2,292,000 | 2,207,000 | 2,070,000 | 1,936,000 |
| EBITDA | 742,000 | 676,000 | 470,000 | (553,000) |
| Net Income | 513,000 | 486,000 | 282,000 | (843,000) |
| Total Assets | 3,970,000 | 3,930,000 | 3,497,000 | 3,388,000 |
| Total Debt | 927,000 | 685,000 | 637,000 | 777,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Hikma Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Hikma Pharmaceuticals‘s full profile, request access.
Request a free trialHikma Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals.
Pharmaceuticals
London, United Kingdom
8,600
As of 2020
00000
000000000
00000
000000 0
rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
000000000000000
Tokyo, Japan
00000
As of 0000
00000000
000 0000
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
000000000000000
Mumbai, India
00000
As of 0000
00.00
0000-00-00
00000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialHikma Pharmaceuticals Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
| 000 00000000000000 | Corporation | Mumbai, India | 00000 | 00000000000 | ||
| 000000 | Corporation | Maharashtra, India | 0000 |
Hikma Pharmaceuticals Executive Team (26)
Hikma Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000 | Self | Board Member | 000 0000 |
| 0000 0000000000 | Hikma Pharmaceuticals | Board Member | 000 0000 |
| 00000 00000000 | Hikma Pharmaceuticals | Director & Vice Chairman | 000 0000 |
| 00000000 000 00-00000 | Self | Board Member | 000 0000 |
| 0000 000000000 | Self | Board Member | 000 0000 |
Hikma Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialHikma Pharmaceuticals Investments & Acquisitions (19)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 (000 | 02-Jan-2019 | 000000000000000000 | 0000.00 | Medical Supplies | 0000 000000000 |
| 000000 00000000000 | 29-Feb-2016 | 000000000000000000 | 00.000 | Pharmaceuticals | 0000 00000000 |
| 0000 000000 000000 | 08-Sep-2015 | 000000000000000000 | 0000 | Drug Discovery | |
| 000000000000000 00 | 17-Sep-2014 | 000000000 00000 00 | Buildings and Property | 0000 00000000 | |
| Bedford Laboratories | 15-Jul-2014 | Merger/Acquisition | 00000 | Medical Supplies | 0000 00000000 |
Hikma Pharmaceuticals Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Hikma Ventures | Corporate Venture Capital | London, United Kingdom | 2015 |
| 00000000000 | Distributors (Healthcare) | Gräfelfing, Germany | 0000 |
| 0000 0000000000000 | Acquirer | Al Salt, Jordan | 0000 |
| 0000000000 | Pharmaceuticals | Casablanca, Morocco | 0000 |
Hikma Pharmaceuticals Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000000000 00 | 17-Sep-2014 | 000000000 00000 00 | Completed |
|
|
| 000 00000 00000000 | 15-Jul-2014 | 000000000000000000 | 00000 | Completed |
|
| Unimark Remedies | 15-Apr-2011 | Corporate | 000.00 | Completed |